1.
两组患者一般资料的比较
Comparison of basic characteristics of patients with drug-induced liver injury (DILI) between relapse group and non-relapse group [n (%)]
| Characteristics | Total (n=1138) | Non-relapse (n=984) | Relapse (n=154) | P |
| BMI: Body mass index; DM: Diabetes mellitus; PT: Prothrombin time; PLT: Platelet; LSM: Liver stiffness measurement; CHE: Cholinesterase; ALT: Alanine aminotransferase; AST: Aspartate transaminase; TBIL: Total bilirubin; ALP: Alkaline phosphatase; GGT: Gamma-glutamyltransferase; ULN: Upper limit of normal range (CHE: 5000 U/L; TBIL: 20.5 μmol/L; ALT: 40 U/L; AST: 40 U/L; GGT: 50 U/L; ALP: 150 U/L). | ||||
| Female (%) | 524(46.0) | 448(45.5) | 76(49.4) | 0.425 |
| Age (year, %) | 0.003 | |||
| ≤44 | 520(45.7) | 468(47.6) | 52(33.8) | |
| 44-60 | 531(46.7) | 447(45.4) | 84(54.5) | |
| > 60 | 87(7.6) | 69(7.0) | 18(11.7) | |
| BMI (kg/m2, %) | 0.918 | |||
| < 24 | 625(54.9) | 541(55.0) | 84(54.5) | |
| 24-28 | 405(35.6) | 351(35.7) | 54(35.1) | |
| ≥28 | 108 (9.5) | 92(9.3) | 16(10.4) | |
| Comorbidity (%) | 0.460 | |||
| None | 999(87.8) | 869(88.3) | 130 (84.4) | |
| DM | 38(3.3) | 30(3.1) | 8(5.2) | |
| Hypertension | 90(7.9) | 76(7.7) | 14 (9.1) | |
| DM & Hypertension | 11(1.0) | 9 (0.9) | 2(1.3) | |
| Pattern (%) | 0.157 | |||
| Cholestatic | 587(51.6) | 517(52.5) | 70(45.5) | |
| Hepatocellular | 236(20.7) | 196(19.9) | 40(25.9) | |
| Mixed | 315(27.7) | 271(27.6) | 44(28.6) | |
| Offending agent (%) | 0.092 | |||
| Herbal | 279(35.1) | 243(36.3) | 36(28.8) | |
| Synthetic drugs | 312(39.3) | 264(39.5) | 48(38.4) | |
| Mixed | 203(25.6) | 162(24.2) | 41(32.8) | |
| PT (s, %) | < 0.001 | |||
| ≥14.3 | 66(5.8) | 43(4.4) | 23(14.9) | |
| < 14.3 | 1072 (94.2) | 941(95.6) | 131 (85.1) | |
| PLT (×109/L, %) | 0.323 | |||
| ≥100 | 1053 (92.5) | 914(92.9) | 139 (90.3) | |
| < 100 | 85(7.5) | 70(7.1) | 15 (9.7) | |
| LSM (kPa, %) | < 0.001 | |||
| < 7.2 | 500(43.9) | 476(48.4) | 24(15.6) | |
| 7.2-8.5 | 103 (9.1) | 94(9.5) | 9(5.9) | |
| 8.5-12.3 | 192(16.9) | 165(16.8) | 27(17.5) | |
| 12.3-13.7 | 42(3.7) | 35(3.6) | 7(4.5) | |
| ≥13.7 | 301(26.4) | 214(21.7) | 87(56.5) | |
| CHE (U/L, %) | < 0.001 | |||
| ≥5000 | 861(75.7) | 799(81.2) | 62(40.3) | |
| 2500-5000 | 251(22.0) | 169(17.2) | 82(53.2) | |
| < 2500 | 26(2.3) | 16(1.6) | 10 (6.5) | |
| TBIL (μmol/L, %) | < 0.001 | |||
| ≤1×ULN | 825(72.5) | 742(75.4) | 83(53.9) | |
| 1-2×ULN | 163(14.3) | 128(13.0) | 35(22.7) | |
| > 2×ULN | 150(13.2) | 114(11.6) | 36(23.4) | |
| ALT (U/L, %) | 0.213 | |||
| ≤1×ULN | 380(33.4) | 338(34.3) | 42(27.2) | |
| 1-2×ULN | 280(24.6) | 240(24.4) | 40(26.0) | |
| > 2×ULN | 478(42.0) | 406(41.3) | 72(46.8) | |
| AST (U/L, %) | < 0.001 | |||
| ≤1×ULN | 403(35.4) | 377(38.3) | 26(16.9) | |
| 1-2×ULN | 367(32.3) | 317(32.2) | 50(32.5) | |
| > 2×ULN | 368(32.3) | 290(29.5) | 78(50.6) | |
| GGT (U/L, %) | 0.001 | |||
| ≤1×ULN | 316(27.8) | 292(29.7) | 24(15.6) | |
| 1-2×ULN | 265(23.3) | 227(23.1) | 38(24.7) | |
| > 2×ULN | 557(48.9) | 465(47.2) | 92(59.7) | |
| ALP (U/L, %) | 0.222 | |||
| ≤1×ULN | 764(67.1) | 670(68.1) | 94(61.0) | |
| 1-2×ULN | 313(27.5) | 263(26.7) | 50(32.5) | |
| > 2×ULN | 61(5.4) | 51(5.2) | 10 (6.5) | |
| Fibrosis stage (%) | < 0.001 | |||
| S0 | 91(8.0) | 88(8.9) | 3(1.9) | |
| S1 | 448(39.4) | 428(43.5) | 20(13.1) | |
| S2 | 322(28.3) | 257(26.1) | 65(42.2) | |
| S3 | 211(18.5) | 168(17.1) | 43(27.9) | |
| S4 | 66(5.8) | 43(4.4) | 23(14.9) | |